Program Discovery Preclinical Phase 1 Phase 2 Phase 3
Influenza CC-42344
(Influenza A PB2 Inhibitor)
Discovery Phase complete
Preclinical Phase in progress
Phase 1 Phase not started
Phase 2 Phase not started
Phase 3 Phase not started

We are developing CC-42344, a novel PB2 inhibitor, for the treatment of influenza. CC-42344 binds to a highly conserved PB2 site of influenza polymerase complex (PB1: PB2: PA) and exhibits a novel mechanism of action. CC-42344 has shown excellent antiviral activity against influenza A strains, including avian pandemic strains and Tamiflu resistant strains, and has favorable pharmacokinetic profiles. CC-42344 is currently in preclinical development and we expect to initiate a Phase 1 study of CC-42344 in the fourth quarter of 2018.